These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 7898938)

  • 1. Biochemical characterization of two isoforms of FLT4, a VEGF receptor-related tyrosine kinase.
    Borg JP; deLapeyrière O; Noguchi T; Rottapel R; Dubreuil P; Birnbaum D
    Oncogene; 1995 Mar; 10(5):973-84. PubMed ID: 7898938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors.
    Pajusola K; Aprelikova O; Pelicci G; Weich H; Claesson-Welsh L; Alitalo K
    Oncogene; 1994 Dec; 9(12):3545-55. PubMed ID: 7970715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.
    Joukov V; Pajusola K; Kaipainen A; Chilov D; Lahtinen I; Kukk E; Saksela O; Kalkkinen N; Alitalo K
    EMBO J; 1996 Jan; 15(2):290-98. PubMed ID: 8617204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation at tyrosine residue 1337 abrogates ligand-dependent transforming capacity of the FLT4 receptor.
    Fournier E; Dubreuil P; Birnbaum D; Borg JP
    Oncogene; 1995 Sep; 11(5):921-31. PubMed ID: 7675451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts.
    Pajusola K; Aprelikova O; Armstrong E; Morris S; Alitalo K
    Oncogene; 1993 Nov; 8(11):2931-7. PubMed ID: 7692369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of murine Flt4 ligand/VEGF-C.
    Fitz LJ; Morris JC; Towler P; Long A; Burgess P; Greco R; Wang J; Gassaway R; Nickbarg E; Kovacic S; Ciarletta A; Giannotti J; Finnerty H; Zollner R; Beier DR; Leak LV; Turner KJ; Wood CR
    Oncogene; 1997 Jul; 15(5):613-8. PubMed ID: 9247316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor.
    Galland F; Karamysheva A; Pebusque MJ; Borg JP; Rottapel R; Dubreuil P; Rosnet O; Birnbaum D
    Oncogene; 1993 May; 8(5):1233-40. PubMed ID: 8386825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts.
    Takahashi T; Shibuya M
    Oncogene; 1997 May; 14(17):2079-89. PubMed ID: 9160888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis.
    Shibuya M; Seetharam L; Ishii Y; Sawano A; Gotoh N; Matsushime H; Yamaguchi S
    Princess Takamatsu Symp; 1994; 24():162-70. PubMed ID: 8983073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells.
    Takahashi T; Yamaguchi S; Chida K; Shibuya M
    EMBO J; 2001 Jun; 20(11):2768-78. PubMed ID: 11387210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines.
    Pajusola K; Aprelikova O; Korhonen J; Kaipainen A; Pertovaara L; Alitalo R; Alitalo K
    Cancer Res; 1992 Oct; 52(20):5738-43. PubMed ID: 1327515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1).
    Yamane A; Seetharam L; Yamaguchi S; Gotoh N; Takahashi T; Neufeld G; Shibuya M
    Oncogene; 1994 Sep; 9(9):2683-90. PubMed ID: 8058332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in human glomeruli, and the identification of VEGF148 mRNA, a novel truncated splice variant.
    Whittle C; Gillespie K; Harrison R; Mathieson PW; Harper SJ
    Clin Sci (Lond); 1999 Sep; 97(3):303-12. PubMed ID: 10464055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers.
    Gunningham SP; Currie MJ; Han C; Robinson BA; Scott PA; Harris AL; Fox SB
    Clin Cancer Res; 2000 Nov; 6(11):4278-86. PubMed ID: 11106244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade.
    Davis-Smyth T; Chen H; Park J; Presta LG; Ferrara N
    EMBO J; 1996 Sep; 15(18):4919-27. PubMed ID: 8890165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
    Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
    Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
    Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway.
    Siemeister G; Schirner M; Weindel K; Reusch P; Menrad A; Marmé D; Martiny-Baron G
    Cancer Res; 1999 Jul; 59(13):3185-91. PubMed ID: 10397264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.
    Joukov V; Pajusola K; Kaipainen A; Chilov D; Lahtinen I; Kukk E; Saksela O; Kalkkinen N; Alitalo K
    EMBO J; 1996 Apr; 15(7):1751. PubMed ID: 8612600
    [No Abstract]   [Full Text] [Related]  

  • 20. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane.
    Oh SJ; Jeltsch MM; Birkenhäger R; McCarthy JE; Weich HA; Christ B; Alitalo K; Wilting J
    Dev Biol; 1997 Aug; 188(1):96-109. PubMed ID: 9245515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.